A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure. (April 2017) - Zeidan, A.; Knaus, H.; Robinson, T.; Zeidner, J.; Blackford, A.; Duffield, A.; Rizzieri, D.; Frattini, M.; Levy, M.Y.; Schroeder, M.; Ferguson, A.; Sheldon, K.; et al.